PROTHENA CORP PUBLIC LTD CO
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2.
Our corporate registered address and office is in Dublin, Ireland and our U.S. operations are in Brisbane, California.
In Dublin, Ireland, we occupy approximately 920 square feet of office spaces under two leases which expire on July 31, 2024.
In Brisbane, California, we occupy approximately 31,157 square feet of office and laboratory space under a sublease with Arcus Biosciences, Inc. which expires on September 30, 2028, unless terminated earlier.
We believe that our facilities are sufficient to meet our current needs.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.